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Abstract
Introduction: The present paper provides a study of the activity of the new 1,3-diazinon-4 derivatives and their acyclic 
precursors under the laboratory cipher PYaTd1, PYaTs2, PYaTs3 and PYaTs4 against microorganisms of the genus 
Proteus, which is of high importance at the moment as the growing resistance of the Proteus to previously highly active 
antibiotics dictates the need to search for effective antimicrobial agents that meet modem safety requirements.
Materials and Methods: The study of the activity of the compounds was carried out on collection and freshly isolated 
strains from patients with different pathologies. The strains were identified using the BIOMIC V3 apparatus (Giles 
Scientific, USA) to verify genus and species identity. The strains used in the study were previously examined for sus­
ceptibility to antibacterial drugs by the Disc Method to assess the presence or absence of resistance. The activity of the 
new compounds was studied by the serial dilution method.
Results: The results of the study showed that the compounds PYaTd1, PYaTs2, PYaTs3 and PYaTs4 show a different 
activity against bacteria of the genus Proteus. The substance PYaTs2 is ineffective. With respect to strains P. mirabilis 
and P. rettgeri, the minimum inhibitory concentration of the compounds PYaTs3, PYaTs4 and PYaTd1 ranges from 4 
pg/ml to 16 pg/ml.
Conclusion: Thus, by the average aggregate indices, regardless of the species and strain of bacteria, the most effective 
compound is PYaTd1, the MIC50 of which is within 10 pg/ml, which proves it to be promising and makes further de­
velopment worthwhile.
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Introduction
Urinary tract infections are amongst the most common bac­
terial infections in humans caused by bacteria of the genus
Proteus (P vulgaris, P  mirabilis, P  rettgeri) (Pellegrino et
al. 2013, Budnik 2015, Liu et al. 2015). In 70% of cases, 
there are protei in cases of urolithiasis (Schaffer et al. 2016). 
P. vulgaris along with Escherichia and Pseudomonas ae­
ruginosa, staphylococci and streptococci, as well as with 
anaerobic clostridia, often complicates the course of puru-
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lent and anaerobic infections. P. mirabilis often insulates 
wounds, forming biofilms, which protects the pathogen 
from the effects of antimicrobial agents and makes treat­
ment difficult (Leblebicioglu and Esen 2003, Schaffer et al. 
2016). P. mirabilis is known as an etiological agent of the 
onset of nosocomial pneumonia (Pаlаgin et al. 2012). There 
is an increased interest towards the role of Proteus in the 
etiology of rheumatoid arthritis (RA) and towards the deve­
lopment of chemotherapeutic drugs which are active against 
protei that can reduce the risk of and/or worsening RA de­
velopment (Ushakova et al. 2001, Disaanayake et al. 2014).
Recent studies have shown that the problems of trea­
ting Proteus infections are linked to a growing number of 
strains resistant to antibiotics. In various countries of the 
world, studies of the resistance of protei to antimicrobial 
agents prove the proliferation of Proteus -  producers of ex­
tended-spectrum p-lactamases (Cremet et al. 2011, Schmie- 
mann et al. 2012, Corvec et al. 2013, Chen et al. 2015).
Despite intensive activities to contain and control anti­
biotic resistance, the problem remains extremely urgent. 
In this regard, WHO has published a list of “priority pa­
thogens”, which includes enterobacteria (Budnik 2015).
The growing resistance of the pathogen to the previ­
ously highly active antibiotics makes it a high priority to 
search for effective antimicrobial agents that meet mo­
dern safety requirements.
Currently, there are opportunities to significantly in­
crease the effectiveness of research on the synthesis of 
new pharmacologically active substances by using mo­
dern computer technologies that allow molecular design 
of target structures with a predictable effect (Filimonov 
and Porojkov 2006, WHO 2017).
New derivatives of 1,3-diazinon-4 and their acyclic 
precursors were created and synthesised by the staff of the 
Department of Organic Chemistry of Pyatigorsk Pharma­
ceutical Institute (Kodonidi 2010, Oganesyan et al. 2013). 
A preliminary analysis of the potential biological proper­
ties of these compounds was carried out using the PASS 
programme, which made it possible to conclude that the 
occurrence of various types of biological activity was 
likely. According to the computer forecast, they should 
have antibacterial actions. The primary screening of fif­
teen new derivatives of diazinon showed that they exhibi­
ted activity against protei. Some promising leaders were 
chosen for further development (Luzhnova et al. 2017).
Goal
To conduct a study of the activity of the new 1,3-dia- 
zinon-4 derivatives and their non-cyclic precursors co­
ded in the laboratory as PYaTd1, PYaTs2, PYaTs3 and 
PYaTs4 for microorganisms of the genus Proteus.
Materials and methods o f research
Investigation of the activity of the compounds PYaTd1, 
PYaTs2, PYaTs3 and PYaTs4 with reference to Proteus 
was carried out on the collection strains: P  mirabilis NIIL
tyal, NIIL tya2 (collection “NIIL”, Astrakhan), P  mira- 
bilis VK 294, VK 299 (State-funded Hospital JSC “SM 
Kirov City Clinical Hospital No. 3”, Astrakhan); isolates
- P  rettgeri SES 11/01, SES 11/02 (isolated from the in­
testines of the patients - Sanitary and Epidemiological 
Station, Astrakhan); P  mirabilis VK 190, VK 194 (isola­
ted from trophic ulcers), P  vulgaris VK 01, VK 02 (isola­
ted from the intestine) - State-funded Hospital JSC “SM 
Kirov City Clinical Hospital No. 3”, Astrakhan.
All the strains used in the work were identified by me­
ans of the BIOMIC V3 software system (Giles Scienti­
fic, USA) to determine their belonging to the genus and 
species by using the bio Merieux APL kit, which inclu­
des strips containing individual biochemical markers, to 
identify protei.
The activity of the compounds was studied by the serial 
dilution method (Navashin and Fomin 1974). In these stu­
dies, the concentration of the substances under study in the 
series of serial dilutions was decreased in a geometric pro­
gression by a factor of 2: 128 pg/ml, 64 pg/ml, 32 pg/ml, 16 
pg/ml, 8 pg/ml, 4 pg/ml, 2 pg/ml, 1 pg/ml, 0.5 pg/ml and 
0.25 pg/ml. Control was the tubes containing meat-pepto­
ne broth (MPB) without adding the compound and micr­
oorganisms (control of the medium sterility), with adding 
microorganisms without adding the substances (positive 
control), inoculations with a solvent (DMSO in equivolu- 
mes) and serial dilution series of the reference substances: 
sulphodimethoxin and streptocid for PYaTs2, PYaTs3 and 
PYaTs4 containing a fragment of sulphanilamide and dap- 
sone for PYaTd1 containing a dapsone fragment.
The quantity of the compound (drug) of 4 mg was dis­
solved in 0.5 ml of dimexide, then 4.5 ml of physiological 
solution was added thereto to prepare a working solution 
from which, by means of dilution, a number of tubes with 
preset concentrations were formed.
To prepare a suspension of bacteria, a one-day culture 
was used. The bacterial suspension (0.05 ml) of a cer­
tain density (0.5 McFarland standard) was added to each 
tube with MPB BCH of a series of dilutions of the tested 
substances, including positive control. This culture was 
incubated for 24 hours at a temperature of +37 °C. At 
the end of this period, the presence of microorganisms 
growth was visually assessed in each of the tubes; then 
the contents of the tubes were centrifuged at 1500 rpm for 
10 minutes. The supernatant was removed. The deposit 
was washed twice with physiologic saline solution. From 
each tube, 0.02 ml of the deposit was plated on Ploskire- 
v ’s medium. The culture was incubated for 24 hours at 
a temperature of +37 °C; then the grown colonies were 
counted, using the BIOMIC V3 microbiology system 
(Giles Scientific, USA). Based on the results obtained, 
the minimum inhibitory concentrations of the compounds
-  MIC50 and MIC90-100 were calculated (LibUSSR.RU 
2014, Semina et al. 2004).
The strains used in this work were previously tested 
for susceptibility to antibacterial drugs by the Disc Test to 
determine the presence or absence of resistance (Semina 
et al. 2004). A set of indicator discs DI-PLS-50-01 (CJSC 
Research Centre for Pharmacotherapy, St. Petersburg) 
was used. The results were read using the BIOMIC V3.
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The results were statistically processed using compu­
ter software BIOSTAT 2009 (Analist Soft Inc., USA). 
The variation series was checked for normality by the 
Kolmogorov-Smirnov criterion. The index of statistical 
significance was determined by the Student’s t-test. Sta­
tistically significant were the variations at p< 0.05-0.01.
Results and discussion
The strains of Proteus used in the work displayed a wide 
range of antibiotic susceptibility: from high sensitivity to 
antibacterial drugs to multidrug resistance (Table 1).
Analysis of the cultured collection strains P. mirabi- 
lis showed that the compounds codified as PYaTs3 and 
PYaTs4 suppress their growth within the concentration 
range of 128-4 pg/ml, with a concentration of 8-4 pg/ 
ml being the MIC50 and 128 pg/ml corresponding to the 
MIC85-M IC 100, i.e. close to bactericidal. These strains 
also displayed sensitivity for the PYaTs2 compound in, 
but within, the concentration ranges of 128-16 pg/ml: 
the MPC50 corresponded in most cases to 32 pg/ml and, 
with 128 pg/ml, the growth rate decreased by 65-6% 
at the most.
The reference drugs for this group of compounds were 
less effective: the MIC50 of sulphadimethoxin was usual­
ly 32 pg/ml and its concentration of 128 pg/ml inhibited 
the growth of 55% of the population at most; MIC50 of 
streptocid was somewhat lower (Table 2) and the effect 
when exposed to 128 pg/ml was similar to that of sulp- 
hadimethoxin.
The compound PYaTdl suppressed the growth of 
strains in the same ranges as PYaTs3 and PYaTs4. In com­
parison with dapsone, it was somewhat less active.
The analysis of cultured freshly isolated strains of 
P. mirabilis showed that the PYaTs3 and PYaTs4 com­
pounds had an MIC50 of 8 pg/ml and, at a concentrati­
on of 128 pg/ml, the growth of 65% of the population at 
most was inhibited. The compound PYaTdl also retained 
its activity within the concentration range of 4-8 pg/ml 
(MIC50) and the concentration of 128 pg/ml corresponded 
to IPC65-70 (Table 3).
The effect of the reference drugs sulphanilamides was 
twice as weak as PYaTs3 and PYaTs4 (Table 3). High ac­
tivity was shown by dapsone.
The analysis of the cultured strains of P  rettgeri iso­
lated from patients showed that the activity of the com­
pounds towards this type of protei is somewhat lower 
than that of P  mirabilis: the range of MIC50 in the PYaTs3 
and PYaTs4 compounds was 8-16 pg /ml, the concen­
tration of 128 pg/ml inhibited the growth of 65-75% of 
the population and the PYaTs2 functioned much more 
weakly (Table 4). The activity of the substance PYaTdl 
towards this species remained at the same level. Sulp- 
hadimethoxin was ineffective. The activity of streptocid 
was higher: its MIC50 was 1-2 pg/ml, the maximum level 
of growth inhibition (128 pg/ml) not exceeding 65%. It 
was dapsone that actively inhibited the growth of the pa­
thogen: at high concentrations, its effect was bactericidal 
and the MIC50 was 1 pg/ml (Table 4).
The results of the cultured P. vulgaris can be seen in 
Table 5, which shows that, for the given type of bacteria, 
the use of the tested compounds and reference drugs is 
less effective. In all the compounds of “s” group, MIC50 
is 64 pg/ml and application of a dose of 128 pg/ml inhi­
bits no more than 60-65% of the population of strains. 
The MIC50 range of PYaTdl shifts to higher concentra­
tions (Table 5) and, at the concentration of 128 pg/ml,
Table 1. Sensitivity of strains of the genus Proteus to antibiotics
Antibiotics
P. m irabilis P  rettgeri P  vulgaris
N IIL  ty a l N IIL  tya2 B K  294 B K  299 B K  190 B K  194 S E S  11/01 S E S 11/02 B K  01 B K  02
Ampicillin R R S R S S S S R R
Amoxicillin-
clavulanate I I S I S S S S R R
Ciprofloxacin R R S I S S S S R R
Gentamicin S S S S S S S S R R
Levofloxacin I I S S S S S S R R
Ceftazidime I I S S S S S S S R
Cefixime S S S S S S S S S S
Cefotaxime R I S S S S S S S S
Cefepime I I S S S S S S S I
Ampicillin-
sulbactam I I S I S S S S R S
Ticarcillin-
clavulanate I I S S S S S S S S
Imipenem S S S I S S S S S S
Ceftriaxone R R S I S I S S S S
Amikacin R I S I S I I I S S
Norfloxacin I I S S S I S S S S
Note: R -  resistant; I -  moderately resistant; S -  sensitive.
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Table 2. Activity of the compounds towards collection strains P. m ira b ilis  (pg/ml)
P  m irabilis N IIL  ty a l P  m irabilis N IIL  tya2
MIC50 MIC„„-,„„ MIC,„ MIC90-100
PYATs2 8 - 16 -
PYATs3 4 128 8 -
PYATs4 4 128 4 -
PYATd1 4 128 4 -
Sulphadimethoxin 16 - 32 -
Streptocide 8 - 16 -
Dapson 1 128 2 128
P  m irabilis В К  294 P  m irabilis В К  299
PYATs2 16 - 16 -
PYATs3 8 - 8 -
PYATs4 8 - 4 -
PYATd1 8 - 4 -
Sulphadimethoxin 32 - 32 -
Streptocide 16 - 16 -
Dapson 2 128 4 128
Table 3. Activity of compounds towards P ro teu s  m ira b ilis  strains (pg/ml) isolated from patients
P  m irabilis B K 194 P  m irabilis B K 190
Compound
MIC50 MIC„„-,„„ MIC50 MIC9 0 - ,0 0
PYATs2 32 - 64 -
PYATs3 8 - 8 -
PYATs4 8 - 8 -
PYATd1 4 - 8 -
Sulphadimethoxin 64 - 128 -
Streptocide 16 - 16 -
Dapson 1 100 1 100
Table 4. Activity of compounds towards P ro teu s  re ttg er i Strains (pg / ml) isolated from patients
P  re ttgeri S E S 11/01 P  rettgeri S E S  11/02Compound
MIC50 MIC„„-,„„ MIC,„ MIC9 0 - ,0 0
PYATs2 64 - 32 -
PYATs3 8 - 8 -
PYATs4 16 - 8 -
PYATd1 8 - 4 -
Sulphadimethoxin 128 - 64 -
Streptocide 1 - 2 -
Dapson 1 128 1 128
Table 5. Activity of compounds towards P ro teu s  vu lg a ris strains (pg/ml) ssolated from patients
P  vulgaris В К  01 P  vulgaris В К  02
Compound
MIC50 MIC„„-,„„ MIC5„ MIC9 0 - ,0 0
PYATs2 64 - 64 -
PYATs3 64 - 64 -
PYATs4 64 - 64 -
PYATd1 32 - 16 -
Sulphadimethoxin 128 - 128 -
Streptocide 128 - 128 -
Dapson 32 128 8 128
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Table 6. Average statistical values of the activity of compounds towards strains of the genus Proteus
Compound MIC5„
M±m, mkg/ml Me±m, mkg/ml
PYATs2 37.6± 7.5*# 32.0±2.3*#
PYATs3 18.8±7.5**## 8.0±3.0**##
PYATs4 18.8±7.6**## 8.0±3.0**##
PYATd1 9.2±2.8 6 .0±1 .0л
Sulphadimethoxin 75.2±15.1 64.0±6.0
Streptocide 34.7±15.6 16.0±6.2
Dapson 5.3±3.0 1.5±1.2
Note: * -  p < 0.05, ** -  p < 0.01 relating to sulphadimethoxin; # 
to dapsone.
65-75% inhibition of the growth of the microorganism 
population can be seen.
The reference drugs sulphadimethoxin and streptocide 
were ineffective: at a concentration of 128 gg/ml, they in­
hibited the growth of no more than 50-65% of the strain. 
The activity of dapsone towards these strains was also 
reduced, but it acted efficiently in the zone of comparati­
vely lower concentrations (Table 5).
Mean values of the activity of the compounds are 
shown in Table 6. It follows from the table that the 
PYaTs3 and PYaTs4 compounds containing a fragment of 
sulphonamides are much more active than the reference 
drugs. PYaTs2 was also more active than the reference 
drugs, but it was inferior to PYaTs3 and PYaTs4, since its 
MIC50 was twice as high.
The PYaTd1 compound, by activity, outperformed 
the compounds containing a fragment of sulphonamide: 
its MIC50 was 2-4 times less. The ability of PYaTd1 to 
suppress the growth of strains of the genus Proteus was 
somewhat inferior to that of the reference drug dapsone.
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